Literature DB >> 2685357

A highly efficient retroviral vector allows detection of the transforming activity of the human c-fps/fes proto-oncogene.

R A Feldman1, D R Lowy, W C Vass, T J Velu.   

Abstract

We have constructed an efficient new retroviral vector containing strong promoting elements derived from the Friend murine leukemia virus (F-MuLV) long terminal repeat (LTR) and have used the vector to demonstrate that overexpression of human c-fps/fes can transform established mouse cells. When a c-fps/fes cDNA was cloned into the vector, this viral DNA and the recovered virus induced very high levels of the c-fps/fes product NCP92 and tumorigenic transformation of NIH 3T3 cells. Compared with an isogenic vector under control of a Moloney MuLV-derived LTR, the vector driven by the F-MuLV LTR induced 3- to 10-times-higher levels of expression of c-fps/fes, a higher level of phosphotyrosine in cellular proteins, and a virus whose transforming activity was 2 orders of magnitude greater. We conclude (i) that normal c-fps/fes can induce morphologic transformation and that its transforming activity is a function of the level of expression of NCP92 and (ii) that the vector based on the F-MuLV LTR is more efficient than the vector driven by a Moloney MuLV LTR in inducing high levels of expression and measurable biological activity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2685357      PMCID: PMC251218     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Helper-independent transformation by unintegrated Harvey sarcoma virus DNA.

Authors:  D R Lowy; E Rands; E M Scolnick
Journal:  J Virol       Date:  1978-05       Impact factor: 5.103

2.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

3.  The protein encoded by the transforming gene of avian sarcoma virus (pp60src) and a homologous protein in normal cells (pp60proto-src) are associated with the plasma membrane.

Authors:  S A Courtneidge; A D Levinson; J M Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  1980-07       Impact factor: 11.205

4.  Harvey murine sarcoma virus: influences of coding and noncoding sequences on cell transformation in vitro and oncogenicity in vivo.

Authors:  T J Velu; W C Vass; D R Lowy; P E Tambourin
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

5.  Structure and sequence of the cellular gene homologous to the RSV src gene and the mechanism for generating the transforming virus.

Authors:  T Takeya; H Hanafusa
Journal:  Cell       Date:  1983-03       Impact factor: 41.582

6.  A cellular protein is immunologically crossreactive with and functionally homologous to the Fujinami sarcoma virus transforming protein.

Authors:  B Mathey-Prevot; H Hanafusa; S Kawai
Journal:  Cell       Date:  1982-04       Impact factor: 41.582

7.  Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes.

Authors:  H Ushiro; S Cohen
Journal:  J Biol Chem       Date:  1980-09-25       Impact factor: 5.157

8.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

9.  A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles.

Authors:  S Cohen; H Ushiro; C Stoscheck; M Chinkers
Journal:  J Biol Chem       Date:  1982-02-10       Impact factor: 5.157

10.  Genomes of murine leukemia viruses isolated from wild mice.

Authors:  S K Chattopadhyay; A I Oliff; D L Linemeyer; M R Lander; D R Lowy
Journal:  J Virol       Date:  1981-09       Impact factor: 5.103

View more
  8 in total

1.  Regulation of c-Fes tyrosine kinase and biological activities by N-terminal coiled-coil oligomerization domains.

Authors:  H Cheng; J A Rogers; N A Dunham; T E Smithgall
Journal:  Mol Cell Biol       Date:  1999-12       Impact factor: 4.272

2.  Promoter methylation blocks FES protein-tyrosine kinase gene expression in colorectal cancer.

Authors:  Jonathan M Shaffer; Thomas E Smithgall
Journal:  Genes Chromosomes Cancer       Date:  2009-03       Impact factor: 5.006

3.  Transfected human beta-polymerase promoter contains a ras-responsive element.

Authors:  P S Kedar; D R Lowy; S G Widen; S H Wilson
Journal:  Mol Cell Biol       Date:  1990-07       Impact factor: 4.272

4.  A point mutation in the N-terminal coiled-coil domain releases c-Fes tyrosine kinase activity and survival signaling in myeloid leukemia cells.

Authors:  H Y Cheng; A P Schiavone; T E Smithgall
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

5.  Ligand-dependent transformation by the receptor for human granulocyte/macrophage colony-stimulating factor and tyrosine phosphorylation of the receptor beta subunit.

Authors:  L B Areces; M Jücker; J A San Miguel; A Mui; A Miyajima; R A Feldman
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

6.  Bimolecular fluorescence complementation demonstrates that the c-Fes protein-tyrosine kinase forms constitutive oligomers in living cells.

Authors:  Jonathan M Shaffer; Sabine Hellwig; Thomas E Smithgall
Journal:  Biochemistry       Date:  2009-06-09       Impact factor: 3.162

7.  Functional specificity of cytoplasmic and transmembrane tyrosine kinases: identification of 130- and 75-kilodalton substrates of c-fps/fes tyrosine kinase in macrophages.

Authors:  L B Areces; P Dello Sbarba; M Jücker; E R Stanley; R A Feldman
Journal:  Mol Cell Biol       Date:  1994-07       Impact factor: 4.272

Review 8.  Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products.

Authors:  Kodappully S Siveen; Kirti S Prabhu; Iman W Achkar; Shilpa Kuttikrishnan; Sunitha Shyam; Abdul Q Khan; Maysaloun Merhi; Said Dermime; Shahab Uddin
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.